The present disclosure describes a method for treating or preventing an inflammatory ocular surface disease or disorder, such as ocular graft-versus-host disease, dry eye, meibomian gland disease, thyroid eye disease, blepharitis, Sjogren's syndrome, peripheral ulcerative keratitis, or Stevens-Johnson syndrome, in a human subject in need thereof, the method comprising (a) administering a topical progesterone composition to the forehead of the subject; (b) administering punctal plugs to the subject; and (c) administering a opical corticosteroid composition, such as loteprednol etabonate ointment, to the eye of the subject. Such administration methods may also be useful in improving corneal health before cataract surgery and/or promoting healing of the cornea after cataract surgery.

Provided is a use of a recombinant cytokine gene derived protein or a fragment thereof for inhibiting the activity of a Coronaviridae virus. The recombinant cytokine gene derived protein includes an amino acid sequence represented by SEQ ID NO: 1, or an amino acid sequence that is at least 90% identical to the amino acid sequence represented by SEQ ID NO: 1. Also provided is a use of the described recombinant cytokine gene derived protein or a fragment thereof in the preparation of a drug for preventing or treating a disease or symptom related to the Coronaviridae virus in a subject.

Provided is a use of a recombinant cytokine gene derived protein or a fragment thereof for inhibiting the activity of a Coronaviridae virus. The recombinant cytokine gene derived protein includes an amino acid sequence represented by SEQ ID NO: 1, or an amino acid sequence that is at least 90% identical to the amino acid sequence represented by SEQ ID NO: 1. Also provided is a use of the described recombinant cytokine gene derived protein or a fragment thereof in the preparation of a drug for preventing or treating a disease or symptom related to the Coronaviridae virus in a subject.

The present invention relates to a method of stabilising a tear film in an individual having an ocular surface inflammatory disorder by providing a compound to an ocular surface of the individual to reduce the synthesis of a cholesterol by a meibum producing tissue.

The present invention relates to a method of stabilising a tear film in an individual having an ocular surface inflammatory disorder by providing a compound to an ocular surface of the individual to reduce the synthesis of a cholesterol by a meibum producing tissue.

In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to a therapeutic treatment or prevention of viral infections such as, for example, COVID-19. In one aspect, the therapeutic treatment combines the administration of doxycycline and/or chemically-modified tetracyclines with resveratrol and ivermectin. In another aspect, the disclosed treatment offers anti-inflammatory effects, can combat the effects of reactive oxygen species, and can inhibit the activity of matrix metalloproteinase enzymes; these combined effects may, in some aspects, be useful in preventing or mediating the effects of the cytokine storm that is associated with poor COVID-19 outcomes including death. In some aspects, dosages of the treatment can be modified to account for COVID-19 comorbidities including, but not limited to, such conditions as diabetes or hypertension.

In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to a therapeutic treatment or prevention of viral infections such as, for example, COVID-19. In one aspect, the therapeutic treatment combines the administration of doxycycline and/or chemically-modified tetracyclines with resveratrol and ivermectin. In another aspect, the disclosed treatment offers anti-inflammatory effects, can combat the effects of reactive oxygen species, and can inhibit the activity of matrix metalloproteinase enzymes; these combined effects may, in some aspects, be useful in preventing or mediating the effects of the cytokine storm that is associated with poor COVID-19 outcomes including death. In some aspects, dosages of the treatment can be modified to account for COVID-19 comorbidities including, but not limited to, such conditions as diabetes or hypertension.

The present disclosure relates to a celastrol or a pharmaceutically acceptable salt thereof, and a use thereof in the manufacture of a medicament for preventing and/or treating a cholestatic liver disease or a liver fibrosis.

The present disclosure relates to a celastrol or a pharmaceutically acceptable salt thereof, and a use thereof in the manufacture of a medicament for preventing and/or treating a cholestatic liver disease or a liver fibrosis.

The invention is directed to natural drug compositions comprising turmeric, boswellia and ginger. Methods for the use of the inventive drug compositions in the treatment of inflammatory disorders and melanoma are within the scope of the invention.